Production (Stage)
Qualigen Therapeutics, Inc.
QLGN
$3.42
-$0.10-2.84%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | 1.63M | 3.23M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | 1.63M | 3.23M |
| Cost of Revenue | 24.70K | -2.50M | -1.18M | -758.20K | 159.20K |
| Gross Profit | -24.70K | 2.50M | 1.18M | 758.20K | -159.20K |
| SG&A Expenses | 4.21M | 4.15M | 4.34M | 5.78M | 6.10M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.40M | 6.71M | 8.21M | 10.08M | 11.30M |
| Operating Income | -5.40M | -6.71M | -8.21M | -10.08M | -11.30M |
| Income Before Tax | -6.16M | -7.78M | -9.22M | -11.27M | -12.47M |
| Income Tax Expenses | 3.90K | -6.40K | -4.20K | 1.00K | 600.00 |
| Earnings from Continuing Operations | -6.16 | -7.77 | -9.21 | -11.27 | -12.48 |
| Earnings from Discontinued Operations | -100.00K | -82.70K | -504.20K | -331.00K | -942.20K |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -6.26M | -7.85M | -9.72M | -11.60M | -13.42M |
| EBIT | -5.40M | -6.71M | -8.21M | -10.08M | -11.30M |
| EBITDA | -5.40M | -6.70M | -8.15M | -9.95M | -11.12M |
| EPS Basic | -33.76 | -56.11 | -87.60 | -111.52 | -132.69 |
| Normalized Basic EPS | -17.94 | -28.64 | -45.10 | -60.79 | -66.36 |
| EPS Diluted | -33.76 | -56.11 | -87.60 | -111.52 | -132.69 |
| Normalized Diluted EPS | -17.94 | -28.64 | -45.10 | -60.79 | -66.36 |
| Average Basic Shares Outstanding | 1.44M | 763.40K | 476.50K | 425.40K | 405.70K |
| Average Diluted Shares Outstanding | 1.44M | 763.40K | 476.50K | 425.40K | 405.70K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |